Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a TH1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited.
Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results / A. Lombardi, G. Bozzi, R. Ungaro, S. Villa, V. Castelli, D. Mangioni, A. Muscatello, A. Gori, A. Bandera. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 12(2021), pp. 657711.1-657711.11.
|Titolo:||Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results|
LOMBARDI, ANDREA (Primo) (Corresponding)
|Parole Chiave:||COVID-19; SARS-CoV-2; RNA vaccine; CTL; antibodies; neutralization test|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||2021|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.3389/fimmu.2021.657711|
|Appare nelle tipologie:||01 - Articolo su periodico|